PLYMOUTH
MEETING, Pa., Sept. 20,
2023 /PRNewswire/ -- Jeffrey M. Dayno, M.D.,
President & CEO of Harmony Biosciences, was named to the 2023
PharmaVoice 100 list for his unwavering commitment to bring
clinical innovation and hope to patients living with rare
neurological diseases. Harmony Biosciences Holdings, Inc.
("Harmony") (Nasdaq: HRMY) is a pharmaceutical company dedicated to
developing and commercializing innovative therapies for patients
with rare neurological diseases.
Established in 2005, the PharmaVoice 100 list honors and
highlights a diverse mix of noteworthy, influential executives –
from the clinic to the C-suite – making important contributions to
the life sciences sector and inspiring meaningful change in support
of patients globally.
"I am honored and humbled to be selected for this prestigious
recognition and to share this platform with an extraordinary group
of transformative leaders in life sciences. Throughout my career, I
have been fortunate to be mentored by exceptional leaders and to
work alongside many talented professionals. These relationships
have helped to shape my leadership style and afforded me the
opportunity to advance my career, while mentoring the next
generation of life sciences leaders," said Dr. Dayno. "At
Harmony Biosciences, we believe that where empathy and innovation
meet, a better life can begin for patients living with neurological
diseases. I am energized by the incredible talent across our
organization and proud to lead this team of dedicated individuals,
as we strive to develop and commercialize innovative treatments to
bring hope to patients living with unmet medical needs."
A former practicing neurologist and faculty member at Jefferson
Medical College, Dr. Dayno brought his experience at the bedside to
the industry 25 years ago and has held various leadership positions
since then. He has been involved in multiple NDA approvals and has
built and led medical teams that have collaborated with commercial
teams in support of several successful drug launches. Dr. Dayno
joined Harmony Biosciences in 2017 as the company's first Chief
Medical Officer and was appointed President and Chief Executive
Officer earlier this year. He has propelled Harmony's growth
strategy forward through advancements in clinical development,
corporate development and building out the company's pipeline.
Dr. Dayno has served as the Industry Representative for the
FDA's Peripheral and Central Nervous System Drugs Advisory
Committee, as well as several FDA industry advisory panels.
Additionally, he sits on the board of Emalex Biosciences, serves on
the board of Life Science Cares Philadelphia, and is a member of
the Board of Visitors of the Lewis Katz School of Medicine at
Temple University.
PharmaVoice 100 honorees are selected from a pool of nominations
submitted by readers, peers, and colleagues.
About Harmony Biosciences
At Harmony Biosciences, we
specialize in developing and delivering treatments for rare
neurological diseases that others often overlook. We believe that
where empathy and innovation meet, a better life can begin for
people living with neurological diseases. Established by Paragon
Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from
a wide variety of disciplines and experiences is driven by our
shared conviction that innovative science translates into
therapeutic possibilities for our patients, who are at the heart of
everything we do. For more information, please visit
www.harmonybiosciences.com.
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-president--ceo-jeffrey-m-dayno-md-named-to-2023-pharmavoice-100-list-of-top-industry-leaders-301932798.html
SOURCE Harmony Biosciences